Diffuse Astrocytic and Oligodendroglial Tumors in Adults
Key Points
Key Points
- Each year, more than 15,000 people in the United States are newly diagnosed with diffuse astrocytic and oligodendroglial tumors, including glioblastoma.
- Recently, several systemic agents and a device have demonstrated improvements in survival when added to surgical and radiation therapies.
- Genetic alterations, specifically Isocitrate Dehydrogenase 1 and 2 (IDH1 and IDH2), have become critical classification and prognostic biomarkers.
Treatment
...atment...
...strocytic and Oligodendroglial Tumors...
...glioma, IDH-mutant, 1p/19q co-deleted, CNS...
...ndation 1.1People with oligodendroglioma...
...is a reasonable alternative to PCV when tox...
...tion 1.2Within the group of people wit...
...oma, IDH-mutant, 1p/19q co-deleted, CN...
Recommendation 1.3People with oligodendrog...
...zolomide is a reasonable alternativ...
...a, IDH-mutant, 1p/19q non-codeleted,...
Recommendation 1.4People with astrocyto...
...ommendation 1.5In astrocytoma, IDH-m...
Astrocytoma, IDH-mutant, 1p/19q non...
...commendation 1.6People with astrocytoma, IDH-...
...cytoma, IDH-mutant, CNS WHO grade 4 (former IDH-mu...
...ommendation 1.7People with astrocytoma, IDH-muta...
Glioblastoma and Other IDH-wildtype Diffuse Gliom...
Recommendation 2.1People with astrocytoma...
...ndation 2.2Concurrent temozolomide a...
...2.3Six months of adjuvant temozolomide shou...
...ommendation 2.4Alternating electric field thera...
...ion 2.5Bevacizumab is NOT recommended fo...
...2.6In people with glioblastoma, IDH-wi...
...mmendation 2.7In people with glioblastoma, IDH-wil...
...commendation 2.8No recommendation for or...
...rrent glioblastoma should be referred for par...
...n 2.9No recommendation for or against a...
...ith diffuse midline glioma should be...
Table 1. Reasonable Doses and Schedules by Recommendation
...able 1. Reasonable Doses and Schedules...